US Supreme Court ‘skinny label’ arguments focus on pleading standards, not patents
By Nick Robertson ( April 30, 2026, 21:17 GMT | Comment) -- Multiple justices of the US Supreme Court appeared wary on Wednesday of an opinion that would change the standard for induced patent infringement during oral arguments in Hikma Pharmaceuticals v. Amarin Pharma. While the case could potentially have massive impacts on the pharmaceutical industry and beyond, the justices instead focused on limited procedural issues.Oral arguments in Hikma Pharmaceuticals v. Amarin Pharma before the US Supreme Court on Wednesday focused little on the policy implications of the Hatch Waxman Act to the pharmaceutical industry, and instead centered largely on procedural issues and evidentiary standards....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.